Estrapronicate/hydroxyprogesterone heptanoate/nandrolone undecanoate

Last updated
EPC/OHPH/NU
Combination of
Estrapronicate Estrogen
Hydroxyprogesterone heptanoate Progestogen
Nandrolone undecanoate Androgen; Anabolic steroid
Clinical data
Trade names Trophobolene, Trophoboline
Other namesEPC/OHPH/NU
Pregnancy
category
  • f
Routes of
administration
Intramuscular injection
Identifiers
CAS Number

Estrapronicate/hydroxyprogesterone heptanoate/nandrolone undecanoate (EPC/OHPH/NU), tentative brand name Trophobolene or Trophoboline, is an injectable combination medication of estrapronicate (EPC; estradiol nicotinate propionate), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and nandrolone undecanoate (NU), an androgen/anabolic steroid, which was never marketed. [1] [2] It contained 1.3 mg EPC, 80 mg OHPH, and 50 mg NU in oil solution and was administered by intramuscular injection. [1] [2] [3] The medication was developed by Théramex in the mid-to-late 1960s. [4] [1] [2] It was studied for use for a variety of indications, including treatment of coronary insufficiency, growth deficiency, and osteoporosis, as well as hormonal disorders in gonadotropin deficiency. [1]

In contrast to other anabolic steroid-containing preparations, EPC/OHPH/NU reportedly had no masculinizing effects, and its estrogenic component likewise reportedly had no feminizing effects. [1] The nicotinic acid (niacin; vitamin B3) derived from estrapronicate was said to enhance the nutrient, relaxant, and antiadipose effects of the estrogenic component. [1]

The pharmacokinetics of nandrolone undecanoate in this combination preparation have been studied as well as compared to nandrolone alone (Dynabolon). [5]

See also

Related Research Articles

<span class="mw-page-title-main">Nandrolone</span> Anabolic steroid

Nandrolone, also known as 19-nortestosterone, is an endogenous androgen which exists in the male body at a ratio of 1:50 compared to testosterone. It is also an anabolic steroid (AAS) which is medically used in the form of esters such as nandrolone decanoate and nandrolone phenylpropionate. Nandrolone esters are used in the treatment of anemias, cachexia, osteoporosis, breast cancer, and for other indications. They are not used by mouth and instead are given by injection into muscle or fat.

<span class="mw-page-title-main">Nandrolone decanoate</span> Anabolic steroid

Nandrolone decanoate, sold under the brand name ROLON among others, is an androgen and anabolic steroid (AAS) medication which is used primarily in the treatment of anemias and wasting syndromes, as well as osteoporosis in menopausal women. It is given by injection into muscle or fat once every one to four weeks.

<span class="mw-page-title-main">Testosterone enanthate</span> Chemical compound

Testosterone enanthate is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels in men. It is also used in hormone therapy for transgender men. It is given by injection into muscle or subcutaneously usually once every one to four weeks.

<span class="mw-page-title-main">Norethisterone</span> Progestin medication

Norethisterone, also known as norethindrone and sold under many brand names, is a progestin medication used in birth control pills, menopausal hormone therapy, and for the treatment of gynecological disorders. The medication is available in both low-dose and high-dose formulations and both alone and in combination with an estrogen. It is used by mouth or, as norethisterone enanthate, by injection into muscle.

<span class="mw-page-title-main">Trenbolone acetate</span> Chemical compound

Trenbolone acetate, sold under brand names such as Finajet and Finaplix among others, is an androgen and anabolic steroid (AAS) medication which is used in veterinary medicine, specifically to increase the profitability of livestock by promoting muscle growth in cattle. It is given by injection into muscle.

<span class="mw-page-title-main">Trestolone</span> Chemical compound

Trestolone, also known as 7α-methyl-19-nortestosterone (MENT), is an experimental androgen/anabolic steroid (AAS) and progestogen medication which has been under development for potential use as a form of hormonal birth control for men and in androgen replacement therapy for low testosterone levels in men but has never been marketed for medical use. It is given as an implant that is placed into fat. As trestolone acetate, an androgen ester and prodrug of trestolone, the medication can also be given by injection into muscle.

Masculinizing hormone therapy, also known as transmasculine hormone therapy, or female-to-male hormone therapy, is a form of hormone therapy and gender affirming therapy which is used to change the secondary sexual characteristics of transgender people from feminine or androgynous to masculine. It is a common type of transgender hormone therapy, and is predominantly used to treat transgender men and other transmasculine individuals. Some intersex people also receive this form of therapy, either starting in childhood to confirm the assigned sex or later if the assignment proves to be incorrect.

<span class="mw-page-title-main">Hydroxyprogesterone heptanoate</span> Chemical compound

Hydroxyprogesterone heptanoate (OHPH), also known as hydroxyprogesterone enanthate (OHPE) and sold under the brand names H.O.P., Lutogil A.P., and Lutogyl A.P. among others, is a progestin medication used for progestogenic indications. It has been formulated both alone and in together with estrogens, androgens/anabolic steroids, and other progestogens in several combination preparations. OHPH is given by injection into muscle at regular intervals.

<span class="mw-page-title-main">Estrapronicate</span> Chemical compound

Estrapronicate, also known as estradiol nicotinate propionate is an estrogen medication and estrogen ester which was never marketed. It was studied as a component of the experimental tristeroid combination drug Trophobolene, which contained nandrolone decanoate, estrapronicate, and hydroxyprogesterone heptanoate.

<span class="mw-page-title-main">Estradiol dienantate</span> Chemical compound

Estradiol dienanthate (EDE), sold under the brand names Climacteron among others, is a long-acting estrogen medication which was previously used in menopausal hormone therapy for women and to suppress lactation in women. It was formulated in combination with estradiol benzoate (EB), a short-acting estrogen, and testosterone enanthate benzilic acid hydrazone (TEBH), a long-acting androgen/anabolic steroid. EDE has not been made available for medical use alone. The medication, in combination with EB and TEBH, was given by injection into muscle once or at regular intervals, for instance once every 6 weeks.

<span class="mw-page-title-main">Androgen ester</span> Class of chemical compounds

An androgen or anabolic steroid ester is an ester of an androgen/anabolic steroid (AAS) such as the natural testosterone or dihydrotestosterone (DHT) or the synthetic nandrolone (19-nortestosterone). Esterification renders AAS into metabolism-resistant prohormones of themselves, improving oral bioavailability, increasing lipophilicity, and extending the elimination half-life. In addition, with intramuscular injection, AAS esters are absorbed more slowly into the body, further improving the elimination half-life. Aside from differences in pharmacokinetics, these esters essentially have the same effects as the parent drugs. They are used in androgen replacement therapy (ART), among other indications. Examples of androgen esters include testosterone esters such as testosterone cypionate, testosterone enanthate, testosterone propionate, and testosterone undecanoate and nandrolone esters such as nandrolone decanoate and nandrolone phenylpropionate.

<span class="mw-page-title-main">Nandrolone phenylpropionate</span> Anabolic steroid

Nandrolone phenylpropionate (NPP), or nandrolone phenpropionate, sold under the brand name Durabolin among others, is an androgen and anabolic steroid (AAS) medication which has been used primarily in the treatment of breast cancer and osteoporosis in women. It is given by injection into muscle once every week. Although it was widely used in the past, the drug has mostly been discontinued and hence is now mostly no longer available.

<span class="mw-page-title-main">Nandrolone undecanoate</span> Chemical compound

Nandrolone undecanoate (NU), also known as nandrolone undecylate, and sold under the brand names Dynabolon, Dynabolin, and Psychobolan, is an androgen and anabolic steroid medication and a nandrolone ester. It was developed in the 1960s, and was previously marketed in France, Germany, Italy, and Monaco, but has since been discontinued and is now no longer known to be available. The pharmacokinetics of nandrolone undecanoate alone (Dynabolon) and in combination with other steroid esters (Trophobolene) have been studied and compared.

<span class="mw-page-title-main">Dimethandrolone</span> Chemical compound

Dimethandrolone (DMA), also known by its developmental code name CDB-1321, is an experimental androgen/anabolic steroid (AAS) and progestogen medication which is under investigation for potential clinical use.

<span class="mw-page-title-main">Dimethandrolone undecanoate</span> Chemical compound

Dimethandrolone undecanoate (DMAU), also known by its developmental code name CDB-4521, is an experimental androgen/anabolic steroid (AAS) and progestogen medication which is under development as a potential birth control pill for men. It is taken by mouth, but can also be given by injection into muscle.

<span class="mw-page-title-main">Androstanolone</span> Androgenic and anabolic steroid medication

Androstanolone, or stanolone, also known as dihydrotestosterone (DHT) and sold under the brand name Andractim among others, is an androgen and anabolic steroid (AAS) medication and hormone which is used mainly in the treatment of low testosterone levels in men. It is also used to treat breast development and small penis in males. Compared to testosterone, androstanolone (DHT) is less likely to aromatize into estrogen, and therefore it shows less pronounced estrogenic side effects, such as gynecomastia and water retention. On the other hand, androstanolone (DHT) show more significant androgenic side effects, such as acne, hair loss and prostate enlargement.

<span class="mw-page-title-main">Lynestrenol phenylpropionate</span> Chemical compound

Lynestrenol phenylpropionate (LPP), also known as ethynylestrenol phenylpropionate, is a progestin and a progestogen ester which was developed for potential use as a progestogen-only injectable contraceptive by Organon but was never marketed. It was assessed at doses of 25 to 75 mg in an oil solution once a month by intramuscular injection. LPP was associated with high contraceptive failure at the low dose and with poor cycle control. The medication was found to produce estrogenic effects in the endometrium in women due to transformation into estrogenic metabolites.

Estradiol diundecylate/hydroxyprogesterone heptanoate/testosterone cyclohexylpropionate (EDU/OHPH/TCHP), sold under the brand name Trioestrine Retard, is an injectable combination medication of estradiol diundecylate (EDU), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and testosterone cyclohexylpropionate (TCHP), an androgen/anabolic steroid. It contained 2.25 mg EDU, 100 mg OHPH, and 67.5 mg TCHP in oil solution, was provided as ampoules, and was administered by intramuscular injection. The medication was manufactured by Roussel and Théramex and was marketed by 1953. It is no longer available.

Estradiol dibutyrate/hydroxyprogesterone heptanoate/testosterone caproate (EDBu/OHPH/TCa), sold under the brand name Triormon Depositum, is an injectable combination medication of estradiol dibutyrate (EDBu), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and testosterone caproate (TCa), an androgen/anabolic steroid, which was used in the treatment of menopausal symptoms in women. It contained 3 mg EDBu, 30 mg OHPH, and 50 mg TCa in oil solution and was administered by intramuscular injection. The medication was developed by 1957. It is no longer available.

Estradiol hexahydrobenzoate/hydroxyprogesterone caproate/testosterone hexahydrobenzoate (EHHB/OHPC/THHB), sold under the brand name Trinestril AP, is an injectable combination medication of estradiol hexahydrobenzoate (EHHB), an estrogen, hydroxyprogesterone caproate (OHPC), a progestogen, and testosterone hexahydrobenzoate (THHB), an androgen/anabolic steroid. It contained 3 mg EHHB, 75 mg OHPC, and 100 mg THHB and was administered by intramuscular injection once per month. The medication was marketed by 1957.

References

  1. 1 2 3 4 5 6 Polish Endocrinology. Państwowy Zakład Wydawnuictw Lekarskich (National Institute of Medical Publishing). 1969. p. 210.
  2. 1 2 3 Vignon G, Pansu D (15 January 1967). "Le traitement de l'ostéoporose par le trophobolène" [The treatment of osteoporosis by trophobolene]. Rev Lyon Med (in French). 16 (1): 31–8. ISSN   0556-798X. PMID   5595570.
  3. Action QA, ed. (21 June 2013). "Nandrolone". Testosterone Congeners—Advances in Research and Application: 2013 Edition: ScholarlyBrief. ScholarlyEditions. pp. 137–. ISBN   978-1-4816-9288-5. Table 1 Oil based long-acting intramuscular injections products [...] Trophobolene: Estrapronicate 1.3 mg [...] Nandrolone undecanoate 50 mg Hydroxyprogesterone heptanoate 80 mg.
  4. Kleemann A, Engel JD (2001). Pharmaceutical substances: syntheses, patents, applications. Thieme. p. 1397. ISBN   978-3-13-558404-1.
  5. Courtot D, Forichon J, Paris J (1983). "Pharmacokinetics of 19-Nortestosterone in Man". Chromatography in Biochemistry, Medicine, and Environmental Research, 1: Proceedings of the 1st International Symposium on Chromatography in Biochemistry, Medicine and Environmental Research, Venice, June 16–17, 1981. Analytical Chemistry Symposia Series. Vol. 13. Amsterdam/Oxford/New York: Elsevier. pp. 95–110.